Corporate Information – Page 2 – Alligator Bioscience

2024-06-26

Regulatory

Alligator Bioscience Announces Substantial Overall Survival Benefit and Unprecedented Duration of Response in the 18-Month Analysis from Mitazalimab OPTIMIZE-1 Phase 2 Study in 1st Line Pancreatic Cancer

Median Overall Survival increased to 14.9 months and survival rate at 18 months was 36.2%, nearly twice as high as the 18.6% previously repo ...

2024-06-25

Regulatory

NOT FOR RELEASE, DISTRIBUTION OR PUBLICATION, DIRECTLY OR INDIRECTLY, IN OR INTO, THE UNITED STATES OF AMERICA, AUSTRALIA, BELARUS, CANADA, ...

2024-06-20

Primary endpoint of OPTIMIZE-1 trial was met, with Objective Response Rate (ORR) of 40.4% in 57 evaluable patients Unprecedented Duration of ...

2024-06-14

Regulatory

Lund, Sweden, June 14, 2024 – Alligator Bioscience (Nasdaq Stockholm: ATORX) today announces the appointment of Johan Giléus as ...

2024-06-03

Publication in world-leading clinical oncology journal validates the quality and potential implications of Phase 2 OPTIMIZE-1 results The st ...

2024-05-23

OPTIMIZE-1 study results showed confirmed ORR of 40.4%, unconfirmed ORR of 50.9% and DCR of 79% in 57 evaluable patients with chemotherapy-n ...

2024-05-21

FDA IND follows promising Phase 2 results presented at 2024 ASCO GI revealing that the addition of HLX22 (AC101) to biosimilar trastuzumab a ...

2024-05-20

Next-generation CD40 agonists have opportunity to address key biological and medical needs in immuno-oncology Bispecific CD40-targeting anti ...

2024-05-14

Study conducted by Moores Cancer Center at University of California San Diego to evaluate safety and efficacy of mitazalimab injected intrat ...